140 related articles for article (PubMed ID: 37216165)
41. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
[No Abstract] [Full Text] [Related]
42. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor.
Ohara M; Matsuura K; Akimoto E; Noma M; Doi M; Nishizaka T; Kagawa N; Itamoto T
Mol Clin Oncol; 2016 Apr; 4(4):648-654. PubMed ID: 27073684
[TBL] [Abstract][Full Text] [Related]
44. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical Analysis Of Novel Biomarkers Cyclin D1, p53 And Ki67 In Endometrial Carcinoma: Clinicopathological Significance And Prognostic Value.
Atram MA; Shivkumar VB; Gangane NM
Gulf J Oncolog; 2022 Jan; 1(38):15-23. PubMed ID: 35156640
[TBL] [Abstract][Full Text] [Related]
46. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
47. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study.
Artac M; Turhal NS; Kocer M; Karabulut B; Bozcuk H; Yalcin S; Karaagac M; Gündüz S; Isik N; Uygun K
Tumori; 2014; 100(2):143-8. PubMed ID: 24852857
[TBL] [Abstract][Full Text] [Related]
48. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
49. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer.
Grabowski JP; Martinez Vila C; Richter R; Taube E; Plett H; Braicu E; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):498-503. PubMed ID: 31996397
[TBL] [Abstract][Full Text] [Related]
50. Long-Term Outcomes of Radical Surgery for Transverse Colon Cancer Staged from I to IIIC.
Jiang Y; Zou Z; Zhang Z; Zhang Y; Sun Y; Liang B
Cancer Manag Res; 2020; 12():13043-13049. PubMed ID: 33376398
[TBL] [Abstract][Full Text] [Related]
51. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
52. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
[TBL] [Abstract][Full Text] [Related]
53. [Effect of adjuvant chemotherapy on the prognosis of stage II( colon cancer patients with high risk factors].
Wu A; Chen P; Sun T; Wang X; Liu X; Yao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Dec; 20(12):1381-1386. PubMed ID: 29280121
[TBL] [Abstract][Full Text] [Related]
54. Effects of oxaliplatin-containing adjuvant chemotherapy on short-term survival of patients with colon cancer in Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Wardhani Y; Hutajulu SH; Ferianti VW; Fitriani Z; Taroeno-Hariadi KW; Kurnianda J
J Gastrointest Oncol; 2019 Apr; 10(2):226-234. PubMed ID: 31032089
[TBL] [Abstract][Full Text] [Related]
55. Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection.
Peng J; Li C; Wang F; Zhang H; Xiao W; Li H; Lu Z; Pan Z; Wu X; Zhang R
Cancer Manag Res; 2018; 10():2095-2103. PubMed ID: 30140160
[TBL] [Abstract][Full Text] [Related]
56. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
57. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
59. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
60. Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years.
Taha HF; Harb OA; Gertallah LM; Abdelaziz LA
J Gastrointest Cancer; 2022 Sep; 53(3):581-591. PubMed ID: 34282542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
